- OmniAb, Inc. (OABI, Financial) launches xPloration Partner Access Program, offering high-throughput single B-cell screening technology to partners.
- The xPloration platform enhances antibody discovery and development with machine learning and AI.
- OmniAb to showcase xPloration at PEGS Boston Summit, highlighting its advanced screening capabilities.
OmniAb, Inc. (OABI) has announced the rollout of the xPloration Partner Access Program, enabling its partners to enhance their antibody discovery processes with the xPloration instrument. This proprietary, high-throughput single B-cell screening platform integrates machine learning and artificial intelligence to transform discovery and development operations.
Matt Foehr, CEO of OmniAb, highlighted that xPloration has been integral to the company's workflow, and after thorough validation, the technology is now available for partners' laboratory use. The platform not only boosts the speed and quality of screening but also adds new revenue channels for OmniAb as it expands its business reach.
Designed to meet the dynamic needs of the biopharmaceutical sector, xPloration uses custom chips with 1.5 million microcapillaries to isolate individual B-cells efficiently. The system's fluidics-free design and quick operation time of approximately 1.5 hours stand out as key features.
Scheduled for the 21st Annual PEGS Boston Summit, OmniAb will present xPloration's capabilities through case studies and discussions led by industry experts, including Dr. Bob Chen and Dr. John Kenney. Attendees can visit the OmniAb exhibit at booth #305 for more details on the technology and the Partner Access Program.
